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frequent in the TS group compared with TR group (p = 0.043). A
significant association between IVS7+24G>A SNP and high TGF-
bR1 protein expression was observed (p = 0.044). Nonetheless,
among all studied polymorphisms only ESR12014G>A SNP was
correlated with a heterogeneous distribution of ERa expression
(r = 0.353, p = 0.016).
Conclusion: These data suggest that the distribution pattern of
ERa expression, EGFR expression and ESR1 2014G>A genetic
variation could be useful additional prognostic markers for
hormone receptor-positive breast cancer patients treated with
adjuvant tamoxifen.
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Tumor markers play an important role in the identification of
human malignancies. It has been shown that the carcinoembry-
onic antigen (CEA, CEACAM5) is a promoter of metastasis in
epithelial cancers that is widely used as a clinical marker. The
aim of this study is to elucidate the network of genes that are
involved in the CEA-induced liver metastasis. Previously, we have
shown that CEA is accumulated in the lungs and livers of rats by
interacting with their macrophages. We identified and cloned a
new gene (CEAR) for the CEA-binding protein, which is located
on the surface of fixed liver macrophages, Kupffer cells (Bajenova
et al, 2001). It has been shown that the interaction of CEA and
CEAR proteins increases the production of IL-1, IL-10, IL-6,
TNF-a cytokines (Thomas et al, 2011). This interaction changes
the expression of liver adhesion molecules that enhances the
survival of cancer cells to the liver. We also suggested that CEA
synthesis by cancer cells may influence the E-cadherin adhesion
junction complexes and have shown that CEA production violates
the functional relationship between Ecadherin and its partners a-,
b- and p120 catenin. A new type of interaction was discovered
between the CEA and b-catenin and the increased amount of
b-catenin in the nuclei of CEA producing cells. The data show that
CEA production can cause the dissociation of cancer cells and
trigger cancer progression. The CEA synthesis also alters splicing
of p120 catenin protein and causes the release of soluble
E-cadherin. Previously, CEA and epithelial E-cadherin were
considered as independent tumor markers. Our data explain
the correlation between the elevated levels of CEA and the
increase in soluble E-cadherin in the progression of colorectal
cancer (Bajenova et al, 2014).
We carried out a comparative transcriptome analysis of CEA-
producing cell lines. The RNA transcriptome libraries were
obtained and sequenced. By pairwise comparisons of CEA pro-
ducing and non-producing cell lines using Cummerband pro-
gram, we selected the set of genes (90 total genes) whose
expression have been changed in the CEA-producing cell lines
(overexpressed or downregulated). The biological processes that
are linked to this differential gene expression were identified by
Gene Set Enrichment Analysis (GSEA). In total, 8 significantly
enriched GO terms related to the cellular components and biolog-
ical processes were identified. Using KEGG and GO databases, we
also identified the signaling pathways involved in the response to
CEA. These findings have direct medical application, since they
allow not only to establish the relationships between the existing
biomarkers but also to discover the new ones. These biomarkers
can be used for diagnosis and monitoring of metastatic carcino-
mas and for the drug development.
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Discovery of new pharmacologically active small molecules is
an important and rapidly expanding area of modern molecular
pharmacology. Given a limited number of proteins that are drug-
gable, it is important to identify as many chemical effectors as
possible to define the best regimen of anti-cancer therapy in each
particular case. An E3 ubiquitin ligase, Mdm2, which mediates
ubiquitin-dependent degradation of the critical tumor suppressor
p53, is a promising target for small molecule inhibitors. Using a
hybrid approach which combines the rational design of small
molecules selected from the virtual library and the high-content
screening using cancer cell lines we discovered several new inhi-
bitors of the p53-Mdm2 interaction. These compounds were able
to activate and stabilize the p53 protein causing massive apopto-
sis preferably in p53-positive cells at rates higher than the well-
known inhibitor of Mdm2, Nutlin-3. The molecular mechanisms
of their action will be discussed.
As another example of rational design of potential anti-cancer
drugs, we will talk about artificial nano-Matrix-Imprinted -
Polymers (MIPs) that recognize the structure of peptides and
other biological molecules and thus dubbed as ‘‘plastic antibod-
ies”. We have generated such nanoparticles against the surface
region of the oncogenic receptor, EGFR, which is overexpressed
in many forms of solid tumors. Selection of the linear epitope
for creating ‘‘plastic antibodies” against the receptor was per-
formed by analysis of a three-dimensional structure of the pro-
tein. The obtained ‘‘plastic antibodies” were specific against the
epitope of EGFR. These plastic antibodies when loaded with a
genotoxic drug, doxorubicin, were able to specifically induce cell
death of breast cancer cell lines that overexpress the EGFR recep-
tor. Experiments in vivo using xenografts of breast cancer cell
lines pre-incubated with these plastic antibodies in nude mice
showed that they have a pronounced therapeutic effect. Further-
more, since the commercial drug, Cetuximab, recognizes an epi-
tope of EGFR, different from the one recognized by our plastic
antibodies, it is likely that the latter may increase the efficacy of
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